Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
iCAD, Inc. provides AI-powered cancer detection and breast health software for radiology providers, centered on the ProFound AI Breast Health Suite and ProFound Cloud. Company news has covered mammography workflow integrations, distribution and reseller partnerships, research presentations in breast cancer detection, risk evaluation, breast density assessment, and breast arterial calcification assessment, along with FDA clearance for ProFound Detection and periodic operating results.
iCAD's later corporate news and filings also document its transition from a Nasdaq-listed public company to a wholly owned subsidiary of RadNet following a completed merger in July 2025.
iCAD, a leader in medical technology, has initiated the GLIOX trial, targeting recurrent glioblastoma using the Xoft® Axxent® Electronic Brachytherapy System. This significant milestone took place at Providence Saint John’s Health Center, led by renowned oncologist Santosh Kesari. The trial aims to compare Xoft IORT with Avastin against traditional treatments, building on promising data from earlier studies. Results showed patients receiving Xoft IORT had longer survival rates and fewer complications, signaling potential advancements in brain tumor therapy.
NASHUA, N.H., Dec. 6, 2021 -- iCAD, a leader in cancer detection and therapy solutions, announced that Stacey Stevens, President and incoming CEO, will present at Oppenheimer’s Imagine AI + Healthcare Investor Summit. The presentation is scheduled for December 7, 2021, from 11:00 a.m. to 11:20 a.m. ET. This event, organized by Oppenheimer in collaboration with the Alliance for AI in Healthcare, highlights advancements in AI technology within healthcare.
For more information, visit www.icadmed.com.
iCAD appointed Stacey Stevens as President and CEO, effective March 1, 2022. Stevens, previously the company's President, joins the Board of Directors, while Michael Klein continues as Chairman. The Board highlighted Stevens' focus on driving change and innovation at a crucial growth phase for iCAD, particularly with recent technology launches in cancer detection and therapy. Stevens aims to enhance patient care and shareholder value through the company's advanced solutions.
iCAD (NASDAQ: ICAD) announced that its advanced breast cancer detection software, ProFound AI, will be highlighted in three scientific presentations at the RSNA 2021 meeting. Key studies focus on ProFound AI's effectiveness in improving cancer detection outcomes in digital breast tomosynthesis (DBT) screenings. Presentations will discuss AI's role in identifying aggressive lesions and its real-world impact on detection rates. Notably, ProFound AI reduces reading time by 52.7% and enhances radiologist sensitivity by 8%. The company continues to advance its technology for better patient care in breast health.
iCAD, Inc. (NASDAQ: ICAD), a leader in medical technology, announced its participation in the 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021, starting at 9:00 AM ET. The company's management will be available for virtual one-on-one meetings with registered investors. iCAD specializes in innovative solutions for cancer detection and therapy. For further details regarding the conference, interested parties can visit Craig-Hallum.com.
iCAD (NASDAQ: ICAD) will host its 2nd annual virtual investor webinar on November 18, 2021, from 3:00 to 4:30 PM ET.
The event will feature leading experts discussing iCAD’s Breast Health Solutions and the innovative Xoft System, enhancing clinical efficiency and patient outcomes.
Key speakers include Angela Fried, MD, and Sally Grady, among others. The webinar will showcase ProFound® AI, a groundbreaking technology for breast cancer detection with proven efficiency improvements.
Registration is available via iCAD's official website.
iCAD reported third quarter 2021 revenues of $9.4 million, marking a 31% increase year-over-year and a 20% sequential rise. Detection revenue grew by 26% while therapy revenue rose 10%. Notably, the Xoft® product revenue saw a 34% sequential increase. Despite these gains, the company experienced a net loss of $2.2 million. The nine-month revenues totaled $25.8 million, up 34% compared to 2020. CEO Mike Klein highlighted ongoing market demand and product launches as critical drivers for future growth.
iCAD (NASDAQ: ICAD) will announce its third-quarter financial results on November 9, 2021, after market close. A conference call is scheduled for 4:30 PM ET, providing an opportunity for investors to gain insights into the company's performance in cancer detection and therapy solutions. The domestic and international call-in numbers are provided, along with a conference ID and a link for the webcast. iCAD continues to position itself as a leader in the medical technology sector.
iCAD, a leader in medical technology, will present its advanced ProFound AI for 2D Mammography at the Journées Francophones de Radiologie in Paris from October 8-11, 2021. This new version shows significant performance improvements: up to 4% increased sensitivity and 10% improved specificity, alongside 40% faster processing times. A new product, ProFound AI Risk, now estimates short-term breast cancer risk based solely on screening mammograms. This technology aims to enhance breast cancer detection and empower women to better manage their healthcare.
iCAD, a leader in medical technology, has launched ProFound AI Risk and an updated PowerLook Density Assessment, enhancing breast cancer screening capabilities. The ProFound AI Risk tool offers personalized short-term breast cancer risk estimations from mammogram images, integrating ethnic data for inclusive screening. This innovation aims to reduce unnecessary procedures and improve patient outcomes. Meanwhile, PowerLook Density Assessment automates breast density evaluation, addressing subjectivity in assessments. These advancements are expected to support clinicians as they navigate post-COVID challenges in breast cancer detection.